Browsing Tag
Madrigal Pharmaceuticals
4 posts
Ribo enters obesity RNAi race as RBD3133 moves toward first human study in Europe
Suzhou Ribo Life Science has filed for a European Phase I trial of RBD3133, taking its first obesity candidate toward human testing as multiple RNAi developers pursue INHBE as a potential fat-selective alternative or complement to incretin therapies.
From metabolism to genetics: Can ARO-PNPLA3 change the MASH playbook
Can ARO-PNPLA3 reshape MASH drug development? Discover how Madrigal Pharmaceuticals, Inc. is expanding into precision therapies.
Mirum Pharmaceuticals (NASDAQ: MIRM) jumps 13% after VISTAS Phase 2b PSC win
Two Phase 2b wins in seven days. A pre-NDA meeting this summer. Mirum is starting to look less like a single-product rare disease story.
Madrigal Pharmaceuticals adds Phase 2 DGAT-2 inhibitor ervogastat to MASH pipeline under global licensing agreement
Find out how Madrigal Pharmaceuticals is expanding its MASH strategy with a global license for ervogastat, a Phase 2 DGAT-2 inhibitor.